Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms

Fig. 1

Outline of next-generation sequencing based sequencing strategy in the context of previously established cohort RAS-alterations defined in Anglesio et al., 2013 [13]. Direct RAS-pathway alterations including suspected and known activating alteration to KRAS, BRAF, ERBB2, FGFR2, and STK11 (the latter is presumed to alleviate negative signals on mTOR via TSC1/2 complex, similar to the effect of ERK1/2 activation)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us